Pentosan Polysulfate

Identification

Name
Pentosan Polysulfate
Accession Number
DB00686  (APRD01175)
Type
Small Molecule
Groups
Approved
Description

A sulfated pentosyl polysaccharide with heparin-like properties. [PubChem]

Structure
Thumb
Synonyms
  • Pentosan sulfuric polyester
  • Pentosane polysulfate
  • Pentosani polysulfas
  • Pentosano polisulfato
  • Pentosanpolysulfat
External IDs
CB-8061 / PZ 68 / SP 54 / UNII-F59P8B75R4
Product Ingredients
IngredientUNIICASInChI Key
Calcium pentosan polysulfateNot AvailableNot AvailableNot applicable
Pentosan polysulfate sodium914032762Y140207-93-8Not applicable
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ElmironCapsule, gelatin coated100 mg/1OralPhysicians Total Care, Inc.2003-12-17Not applicableUs
ElmironCapsule100 mgOralJanssen Pharmaceuticals1993-12-31Not applicableCanada
ElmironCapsule, gelatin coated100 mg/1OralCardinal Health1996-09-26Not applicableUs
ElmironCapsule, gelatin coated100 mg/1OralJanssen Pharmaceuticals1996-09-26Not applicableUs50458 0098 01 nlmimage10 2a15954c
International/Other Brands
Comfora (Swati Spentose Pvt. Ltd.) / Fibrase (Teofarma) / Fibrezym (Bene) / Hemoclar (Sanofi Winthrop) / Hémoclar (Sanofi-Aventis) / Tavan-SP (Sanofi-Aventis) / Thrombocid (Bene-Chemie)
Categories
UNII
F59P8B75R4
CAS number
37300-21-3
Weight
Average: 602.497
Monoisotopic: 601.922340398
Chemical Formula
C10H18O21S4
InChI Key
FCCNSUIJIOOXEZ-SJYYZXOBSA-N
InChI
InChI=1S/C10H18O21S4/c11-3-1-26-10(8(31-35(22,23)24)5(3)28-32(13,14)15)27-4-2-25-9(12)7(30-34(19,20)21)6(4)29-33(16,17)18/h3-12H,1-2H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)/t3-,4-,5+,6+,7-,8-,9-,10+/m1/s1
IUPAC Name
[(2S,3R,4S,5R)-5-hydroxy-2-{[(3R,4S,5R,6R)-6-hydroxy-4,5-bis(sulfooxy)oxan-3-yl]oxy}-4-(sulfooxy)oxan-3-yl]oxidanesulfonic acid
SMILES

Pharmacology

Indication

For the relief of bladder pain or discomfort associated with interstitial cystitis.

Structured Indications
Pharmacodynamics

Pentosan polysulfate sodium is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects.

Mechanism of action

Pentosan polysulfate is a polymer of xylose hydrogen sulfate and contains two sulfate groups per carbohydrate monomer. It binds Fibroblast growth factors (FGFs) as well as other heparin-binding growth factors. It has been shown to interact also with the heparin-binding site of FGFR-1. It inhibits the growth of SW13 adrenocortical cells transfected with FGF-4 and tumorigenicity of MCF-7 breast carcinoma cells transfected with FGF-1 or FGF-4.

TargetActionsOrganism
AFibroblast growth factor 2
antagonist
Human
AFibroblast growth factor 1
antagonist
Human
UFibroblast growth factor 4
inhibitor
Human
Absorption

Slow

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

4.8 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneLimonene, (+)- may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
AbciximabPentosan Polysulfate may increase the anticoagulant activities of Abciximab.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Pentosan Polysulfate is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolPentosan Polysulfate may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Pentosan Polysulfate.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Withdrawn
AllylestrenolThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
AlprostadilThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Alprostadil.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Pentosan Polysulfate.Approved
AltrenogestThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Altrenogest.Vet Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
AnagrelideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Anagrelide.Approved
AncrodPentosan Polysulfate may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Andrographolide.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Pentosan Polysulfate.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
Antithrombin III humanPentosan Polysulfate may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanPentosan Polysulfate may increase the anticoagulant activities of Apixaban.Approved
ApocyninApocynin may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
ApremilastApremilast may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
ArdeparinPentosan Polysulfate may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanPentosan Polysulfate may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Azelastine.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
BecaplerminPentosan Polysulfate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
BeraprostThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Beraprost.Investigational
BevoniumBevonium may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
BivalirudinPentosan Polysulfate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
BucillamineBucillamine may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
BuflomedilThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Buflomedil.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
ButylphthalideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Butylphthalide.Investigational
CangrelorThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Cangrelor.Approved
CaplacizumabCaplacizumab may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Pentosan Polysulfate.Experimental, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
CertoparinPentosan Polysulfate may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineChloroquine may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Pentosan Polysulfate.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
CilostazolThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Cilostazol.Approved
Citric AcidPentosan Polysulfate may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Clopidogrel.Approved
CloricromenThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Cloricromen.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
CurcuminCurcumin may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
Dabigatran etexilatePentosan Polysulfate may increase the anticoagulant activities of Dabigatran etexilate.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Pentosan Polysulfate.Experimental
DalteparinPentosan Polysulfate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPentosan Polysulfate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanPentosan Polysulfate may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Defibrotide.Approved, Investigational
DemegestoneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
DesirudinPentosan Polysulfate may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
DesogestrelThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Desogestrel.Approved
DextranPentosan Polysulfate may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Pentosan Polysulfate may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Pentosan Polysulfate may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Pentosan Polysulfate may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
DicoumarolPentosan Polysulfate may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
DienogestThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Pentosan Polysulfate.Approved
DiphenadioneDiphenadione may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Dipyridamole.Approved
DitazoleDitazole may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Withdrawn
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
DydrogesteroneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
Edetic AcidPentosan Polysulfate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPentosan Polysulfate may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinPentosan Polysulfate may increase the anticoagulant activities of Enoxaparin.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Pentosan Polysulfate.Experimental
EpinastineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Epinastine.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Pentosan Polysulfate.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Eplivanserin.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with eplivanserine.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Epoprostenol.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Eptifibatide.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Pentosan Polysulfate.Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
EstroneEstrone may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
Ethyl biscoumacetatePentosan Polysulfate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
ExisulindExisulind may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
FentiazacFentiazac may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
Ferulic acidPentosan Polysulfate may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Withdrawn
FluindionePentosan Polysulfate may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Pentosan Polysulfate.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
FondaparinuxPentosan Polysulfate may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumPentosan Polysulfate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexatePentosan Polysulfate may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Pentosan Polysulfate.Investigational
GestodeneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
HeminHemin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
HeparinPentosan Polysulfate may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Pentosan Polysulfate.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
HydroxytyrosolThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Hydroxytyrosol.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Pentosan Polysulfate.Approved
IbudilastThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ibudilast.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Pentosan Polysulfate.Approved
Icosapent ethylThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Icosapent ethyl.Approved, Nutraceutical
IdraparinuxPentosan Polysulfate may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ifenprodil.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ifetroban.Investigational
IloprostThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Iloprost.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
IndobufenThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Indobufen.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
IsoxicamIsoxicam may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ketanserin.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
LepirudinPentosan Polysulfate may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanPentosan Polysulfate may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Pentosan Polysulfate.Approved, Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Linsidomine.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
LonazolacLonazolac may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
Megestrol acetateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MelagatranPentosan Polysulfate may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
MestranolMestranol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Pentosan Polysulfate.Investigational, Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Pentosan Polysulfate.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
MethylestrenoloneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Methylestrenolone.Experimental
MilrinoneThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Milrinone.Approved
MizoribineMizoribine may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Pentosan Polysulfate.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Pentosan Polysulfate.Approved
NadroparinPentosan Polysulfate may increase the anticoagulant activities of Nadroparin.Approved
NafamostatPentosan Polysulfate may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Naftopidil.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
NifenazoneNifenazone may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nimesulide.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nintedanib.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nitroaspirin.Investigational
NomegestrolThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Norgestrienone.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Obinutuzumab.Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Pentosan Polysulfate is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Nutraceutical
OrgoteinOrgotein may increase the anticoagulant activities of Pentosan Polysulfate.Vet Approved
OtamixabanPentosan Polysulfate may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
ParecoxibParecoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
Pentaerythritol TetranitratePentosan Polysulfate may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Pentoxifylline.Approved, Investigational
PhenindionePentosan Polysulfate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonPentosan Polysulfate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
PicotamideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Picotamide.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Experimental, Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Prasugrel.Approved
ProgesteroneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
PromegestoneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Pentosan Polysulfate.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
Protein CPentosan Polysulfate may increase the anticoagulant activities of Protein C.Approved
Protein S humanPentosan Polysulfate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePentosan Polysulfate may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ramatroban.Investigational
RelcovaptanThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Relcovaptan.Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Resveratrol.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Pentosan Polysulfate.Approved
ReviparinPentosan Polysulfate may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ridogrel.Approved
RivaroxabanPentosan Polysulfate may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Pentosan Polysulfate.Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Pentosan Polysulfate.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
SarpogrelateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Sarpogrelate.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Pentosan Polysulfate.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Pentosan Polysulfate.Approved
SemapimodSemapimod may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Pentosan Polysulfate.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Sevoflurane.Approved, Vet Approved
SRT501The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with SRT501.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Pentosan Polysulfate.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
SulindacSulindac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
SulodexidePentosan Polysulfate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TenidapTenidap may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Pentosan Polysulfate.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tesmilifene.Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TiboloneTibolone may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
TicagrelorThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ticlopidine.Approved
TinoridineTinoridine may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
TirofibanThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tirofiban.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TolmetinTolmetin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TositumomabThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tositumomab.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tranilast.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Trapidil.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
TribenosideTribenoside may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
TriflusalThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Triflusal.Approved, Investigational
TriptolideTriptolide may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TroxerutinPentosan Polysulfate may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Pentosan Polysulfate.Investigational, Withdrawn
Vitamin EVitamin E may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Vorapaxar.Approved
WarfarinPentosan Polysulfate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPentosan Polysulfate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Pentosan Polysulfate.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
Food Interactions
  • Take on an empty stomach, 1 hour before or 2 hours after meals.

References

Synthesis Reference

Pandurang Balwant Deshpande, Parvenkumar Luthra, Anand Kumar Pandey, Dinesh Jayntibhai Paghdar, Phani,Sharma,Gowthamaiah Vemavarapu Govardhana, "PROCESS FOR THE PREPARATION OF PENTOSAN POLYSULFATE OR SALTS THEREOF." U.S. Patent US20100105889, issued April 29, 2010.

US20100105889
General References
  1. Ghosh P, Smith M: Osteoarthritis, genetic and molecular mechanisms. Biogerontology. 2002;3(1-2):85-8. [PubMed:12014849]
External Links
Human Metabolome Database
HMDB14824
PubChem Compound
37720
PubChem Substance
46509187
ChemSpider
34595
Therapeutic Targets Database
DAP001025
PharmGKB
PA164774806
RxList
RxList Drug Page
ATC Codes
C05BA04 — Pentosan polysulfate sodiumG04BX15 — Pentosan polysulfate sodium
AHFS Codes
  • 92:00.00 — Miscellaneous Therapeutic Agents
FDA label
Download (59.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentProstatitis1
2Enrolling by InvitationTreatmentBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders1
3CompletedSupportive CareDiarrhea / Radiation Enteritis1
4TerminatedTreatmentInterstitial Cystitis1

Pharmacoeconomics

Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg
Capsule, gelatin coatedOral100 mg/1
Prices
Unit descriptionCostUnit
Elmiron 100 mg capsule3.32USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5180715No1993-01-192010-01-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP-8Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.49 mg/mLALOGPS
logP-2.5ALOGPS
logP-11ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)-2.9ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge-4ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area322.55 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity96.38 m3·mol-1ChemAxon
Polarizability46.17 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5
Blood Brain Barrier+0.8606
Caco-2 permeable-0.6462
P-glycoprotein substrateNon-substrate0.7185
P-glycoprotein inhibitor IInhibitor0.6326
P-glycoprotein inhibitor IINon-inhibitor0.9889
Renal organic cation transporterNon-inhibitor0.8869
CYP450 2C9 substrateNon-substrate0.9008
CYP450 2D6 substrateNon-substrate0.8275
CYP450 3A4 substrateNon-substrate0.6053
CYP450 1A2 substrateNon-inhibitor0.8007
CYP450 2C9 inhibitorNon-inhibitor0.8387
CYP450 2D6 inhibitorNon-inhibitor0.8982
CYP450 2C19 inhibitorNon-inhibitor0.8044
CYP450 3A4 inhibitorNon-inhibitor0.9891
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.964
Ames testNon AMES toxic0.6383
CarcinogenicityNon-carcinogens0.5703
BiodegradationNot ready biodegradable0.8772
Rat acute toxicity2.3876 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8908
hERG inhibition (predictor II)Non-inhibitor0.7929
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
O-glycosyl compounds
Alternative Parents
Disaccharides / Sulfuric acid monoesters / Oxanes / Alkyl sulfates / Secondary alcohols / Hemiacetals / Oxacyclic compounds / Acetals / Organic oxides / Hydrocarbon derivatives
Substituents
Disaccharide / O-glycosyl compound / Oxane / Sulfuric acid ester / Alkyl sulfate / Sulfate-ester / Sulfuric acid monoester / Organic sulfuric acid or derivatives / Hemiacetal / Secondary alcohol
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Ligand-dependent nuclear receptor transcription coactivator activity
Specific Function
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name
FGF2
Uniprot ID
P09038
Uniprot Name
Fibroblast growth factor 2
Molecular Weight
30769.715 Da
References
  1. Zugmaier G, Favoni R, Jaeger R, Rosen N, Knabbe C: Polysulfated heparinoids selectively inactivate heparin-binding angiogenesis factors. Ann N Y Acad Sci. 1999;886:243-8. [PubMed:10667230]
  2. Mucha S, Melen-Mucha G, Stepien T, Godlewski A, Stepien H: Effects of pentosan polysulfate sodium on the estrogen-induced pituitary prolactinoma in Fischer 344 rats. Oncol Rep. 2002 Nov-Dec;9(6):1385-9. [PubMed:12375053]
  3. Pluda JM, Shay LE, Foli A, Tannenbaum S, Cohen PJ, Goldspiel BR, Adamo D, Cooper MR, Broder S, Yarchoan R: Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst. 1993 Oct 6;85(19):1585-92. [PubMed:7692072]
  4. McLeskey SW, Zhang L, Kharbanda S, Kurebayashi J, Lippman ME, Dickson RB, Kern FG: Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res Treat. 1996;39(1):103-17. [PubMed:8738610]
  5. Jerebtsova M, Wong E, Przygodzki R, Tang P, Ray PE: A novel role of fibroblast growth factor-2 and pentosan polysulfate in the pathogenesis of intestinal bleeding in mice. Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H743-50. Epub 2006 Oct 27. [PubMed:17071728]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
S100 protein binding
Specific Function
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name
FGF1
Uniprot ID
P05230
Uniprot Name
Fibroblast growth factor 1
Molecular Weight
17459.58 Da
References
  1. Pascu C, Ljungh A, Wadstrom T: Staphylococci bind heparin-binding host growth factors. Curr Microbiol. 1996 Apr;32(4):201-7. [PubMed:8867461]
  2. Zenjari C, Boilly-Marer Y, Desbiens X, Oudghir M, Hondermarck H, Boilly B: Experimental evidence for FGF-1 control of blastema cell proliferation during limb regeneration of the amphibian Pleurodeles waltl. Int J Dev Biol. 1996 Oct;40(5):965-71. [PubMed:8946244]
  3. Jerebtsova M, Wong E, Przygodzki R, Tang P, Ray PE: A novel role of fibroblast growth factor-2 and pentosan polysulfate in the pathogenesis of intestinal bleeding in mice. Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H743-50. Epub 2006 Oct 27. [PubMed:17071728]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Heparin binding
Specific Function
Plays an important role in the regulation of embryonic development, cell proliferation, and cell differentiation. Required for normal limb and cardiac valve development during embryogenesis.
Gene Name
FGF4
Uniprot ID
P08620
Uniprot Name
Fibroblast growth factor 4
Molecular Weight
22047.355 Da
References
  1. Zugmaier G, Lippman ME, Wellstein A: Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst. 1992 Nov 18;84(22):1716-24. [PubMed:1279186]
  2. McLeskey SW, Zhang L, Kharbanda S, Kurebayashi J, Lippman ME, Dickson RB, Kern FG: Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res Treat. 1996;39(1):103-17. [PubMed:8738610]
  3. Wellstein A, Zugmaier G, Califano JA 3rd, Kern F, Paik S, Lippman ME: Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst. 1991 May 15;83(10):716-20. [PubMed:1708834]

Drug created on June 13, 2005 07:24 / Updated on January 14, 2018 10:05